about
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.Pre-clinical and clinical significance of heparanase in Ewing's sarcoma.IDN 5390: an oral taxane candidate for protracted treatment schedulesAntitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants.Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells.Strategies to Strike Survival Networks in Cancer.Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.Targeting heparan sulfate proteoglycans and their modifying enzymes to enhance anticancer chemotherapy efficacy and overcome drug resistance.Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.Structure elucidation of clavilactone D: an inhibitor of protein tyrosine kinases.Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin.Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel.Targeting RET for thyroid cancer therapy.Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.Synthetic sulfoglycolipids targeting the serine-threonine protein kinase Akt.DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.Novel Symmetrical Benzazolyl Derivatives Endowed with Potent anti-Heparanase Activity
P50
Q34078370-2DDFBE92-BF5F-4C4D-ACDD-057A92E12229Q34258443-C5C1CEC0-39C4-48FA-B3A1-61A49F5FBE1FQ34664539-6D38C9EE-09DC-43C5-918E-998E3FFAC2B9Q36648815-1248E577-13A7-4281-8142-3F6EA62D0C58Q36694822-90C83B78-5ED3-4AAE-8E83-39196DC60BC8Q37565298-BFC80D06-8461-43FC-AC3E-B46E28BC4E4EQ38081529-741FAE8D-3009-4A76-99DB-3BE84CA8D2F0Q38425184-2B3036C3-2450-497B-A498-1468A34965D7Q38500023-49173917-45C4-4092-BCD3-0CB6281608ECQ38918627-4A5C3F36-8BF5-4369-B1A9-08F3D5E2E506Q39020309-C2F852C7-EC41-4CE9-8506-EBAD324B48BAQ39028698-195366A7-0C5B-4280-BCCB-7FB78A619912Q39054890-44B4CBB4-D315-4034-91A4-5E762E50E56AQ39142496-B17E187A-FFCA-45BC-BC38-0A6C08F46E31Q39184529-28D91487-9D84-4F5E-A156-DA28642A0245Q39412894-4DB32165-2F9E-4E7B-A583-7D030439DA27Q39509796-D94632E5-5A47-4813-BA28-885BC2DE2604Q39833233-7DE69893-6B53-4BF9-971F-C64254B977ECQ39901958-A6091790-B1C6-410E-B990-024EE39665E9Q40229765-AA007727-AEDB-4B96-941E-430E35B668F5Q40271025-3FE7173E-3DB5-4567-BE20-7B53CB07BCC3Q40610155-91A6E596-D9B5-4777-964C-5C8132315EA8Q40782148-8BE9542A-28A5-4254-A3C7-72BA6EC95587Q40878489-2DA06961-5FD0-46B5-87C6-EF04C7249F1AQ40881685-85CE1378-7B78-4BE6-ABF7-F843E5AD23ECQ41012776-C42A0FFD-18AA-4C03-890B-7533221BB4E5Q42805553-FF3301BD-3F1F-40AF-B74E-4DD20D6FBA9CQ42828399-31ABB7C3-677A-47A8-916C-16FCCA7B2735Q43045056-4A5FCE8A-F2B6-4FE1-B6FD-CECDF1E87065Q44564981-0269786F-6F8E-4900-9E9B-7E41039FF7ECQ45007431-73D6BCA5-1520-4518-86EE-D8302DFDD652Q45881555-BE3262E0-A81A-4D18-8F59-030522A27FEAQ47174310-3BEEF84A-DB83-44F0-A3F6-BF1AF1A0A273Q47887869-08AC9236-7FEC-41C4-BECF-DE7618636F21Q48089220-23436472-AE9E-4128-A373-A6F538C76978Q48960534-3DC13277-2E5F-4D29-B5CB-9652517480DDQ51697031-A7DC99EB-9F68-42FA-9505-6B3EB0D34793Q53262436-B3AB3008-96EE-42F9-AF80-1B31562186E8Q54515616-F901E6BF-043F-4B17-80F4-57F8B9633CD7Q58566358-64A2464C-1BB4-4B0B-8AD0-AFA4D4D11688
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuliana Cassinelli
@ast
Giuliana Cassinelli
@en
Giuliana Cassinelli
@es
Giuliana Cassinelli
@nl
Giuliana Cassinelli
@sl
type
label
Giuliana Cassinelli
@ast
Giuliana Cassinelli
@en
Giuliana Cassinelli
@es
Giuliana Cassinelli
@nl
Giuliana Cassinelli
@sl
prefLabel
Giuliana Cassinelli
@ast
Giuliana Cassinelli
@en
Giuliana Cassinelli
@es
Giuliana Cassinelli
@nl
Giuliana Cassinelli
@sl
P1053
K-7591-2016
P106
P1153
7005620719
P21
P31
P3829
P496
0000-0003-4648-2562